Sugi Predict

Sugi Predict / Targets / CLK1

CLK1

Dual specificity protein kinase CLK1 · P49759 · CLK1 on Sugi Atlas →

120,746 patent compounds predicted against CLK1, 82,881 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL159986 SCHEMBL159986 0.60 11/20
SCHEMBL144533 SCHEMBL144533 0.51 11/20
SCHEMBL154725 SCHEMBL154725 0.42 11/20
SCHEMBL153315 SCHEMBL153315 0.42 11/20
SCHEMBL148056 SCHEMBL148056 0.39 9/20
SCHEMBL11827 SCHEMBL11827 0.56 8/20
SCHEMBL121775 SCHEMBL121775 0.67 7/20
SCHEMBL100069 SCHEMBL100069 0.48 7/20
SCHEMBL23608 SCHEMBL23608 0.43 7/20
SCHEMBL10459 SCHEMBL10459 0.45 6/20
SCHEMBL24327 SCHEMBL24327 0.44 5/20
SCHEMBL145566 SCHEMBL145566 0.70 4/20
SCHEMBL142464 SCHEMBL142464 0.49 4/20
SCHEMBL149464 SCHEMBL149464 0.47 4/20
SCHEMBL157551 SCHEMBL157551 0.47 4/20
SCHEMBL153428 SCHEMBL153428 0.44 4/20
SCHEMBL84029 SCHEMBL84029 0.57 3/20
SCHEMBL46742 SCHEMBL46742 0.47 3/20
SCHEMBL96459 SCHEMBL96459 0.46 3/20
SCHEMBL155481 SCHEMBL155481 0.44 3/20

Clinical trials — most relevant to CLK1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Acelarin First Line Randomised Pancreatic Study PHASE2/PHASE3SUSPENDED
Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma PHASE2/PHASE3UNKNOWN
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy PHASE2COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Trial of Metformin for Colorectal Cancer Risk Reduction for History of Colorectal Adenomas and Elevated BMI PHASE2COMPLETED
Biological Effects of Quercetin in COPD PHASE1/PHASE2UNKNOWN
PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia PHASE2ACTIVE_NOT_RECRUITING
Biological Effects of Quercetin in COPD Phase II PHASE2UNKNOWN
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer PHASE1/PHASE2COMPLETED
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients PHASE2COMPLETED
Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases PHASE1COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 PHASE1COMPLETED
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease. PHASE1COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
A Study of PD1 Combined With Dc-cik in the Treatment of Solid Tumors EARLY_PHASE1UNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation nanCOMPLETED
Rostock International Parkinson's Disease Study (ROPAD) nanCOMPLETED
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
LRRK2 Activity and Markers of Parkinson's Disease in G2385R Carriers nanCOMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Association of Autophagy-related Genes ,LncRNA and SNPs With Colorectal Cancer in Egyptian Population nanCOMPLETED
Natural History, Pathogenesis and Outcome of Melorheostosis A Rare Osteosclerotic Disease nanRECRUITING
Strategy for Management of Patients With Hereditary Cancer Syndromes (HCS) in a Rural Environment nanENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a CLK1 binder may also engage these)

ProteinNameSimilarity
CLK4 Dual specificity protein kinase CLK4 1.000 landscape →
P22518 — 1.000 P22518 →
O35493 — 1.000 O35493 →
Q63117 — 0.999 Q63117 →
Q3SX21 — 0.999 Q3SX21 →
O35491 — 0.998 O35491 →
O35492 — 0.995 O35492 →
CLK3 Dual specificity protein kinase CLK3 0.994 landscape →
CLK2 Dual specificity protein kinase CLK2 0.990 landscape →
Q4FCZ5 — 0.984 Q4FCZ5 →
Q5BAE1 — 0.983 Q5BAE1 →
Q4WYR6 — 0.983 Q4WYR6 →
Q5SN53 — 0.983 Q5SN53 →
Q9LV37 — 0.983 Q9LV37 →
A2X0M1 — 0.982 A2X0M1 →
Q0E459 — 0.982 Q0E459 →
C0RW22 — 0.982 C0RW22 →
Q8VZD5 — 0.982 Q8VZD5 →
Q53N72 — 0.982 Q53N72 →
P51138 — 0.982 P51138 →
Q5VP69 — 0.982 Q5VP69 →
Q9FGW5 — 0.981 Q9FGW5 →
Q03957 — 0.981 Q03957 →
O35831 — 0.981 O35831 →
Q75KK8 — 0.981 Q75KK8 →
O23145 — 0.980 O23145 →
O35832 — 0.980 O35832 →
B0VXL7 — 0.980 B0VXL7 →
Q23357 — 0.980 Q23357 →
P43289 — 0.979 P43289 →